Material Safety Data Sheet

Hazard Alert Code Key:

EXTREME  HIGH  MODERATE  LOW

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME
Methotrexate

STATEMENT OF HAZARDOUS NATURE

NFPA

FLAMMABILITY  HEALTHINESS  INERTNESS

SUPPLIER
Company: Santa Cruz Biotechnology, Inc.
Address: 2145 Delaware Ave
Santa Cruz, CA 95060
Telephone: 800.457.3801 or 831.457.3800
Emergency Tel: CHEMWATCH: From within the US and Canada: 877-715-9305
Emergency Tel: From outside the US and Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112

PRODUCT USE
Antineoplastic agent which acts as an antimetabolite of folic acid. Possesses immunosuppressant properties. Methotrexate competitively inhibits the enzyme dihydrofolate reductase which is necessary for purine and pyrimidine synthesis and consequently prevents the formation of DNA and RNA. Used in the management of acute lymphoblastic leukaemia and in the prophylaxis and treatment of meningeal leukaemia. Effective in the treatment of choriocarcinoma and other trophoblastic tumours. Used in association with other antineoplastic agents in the treatment of lymphosarcoma, Burkitt's lymphoma, osteogenic sarcoma and tumours of the brain, breast, cervix, neck and head, lung, ovary and testes. Has also been employed in the treatment of severe psoriasis. Given by mouth or, as the sodium salt, by injection. Methotrexate interferes with th synthesis of DNA thereby causing death in rapidly multiplying cancerous cells.

SYNONYMS
C20-H22-N8-O5, "4-amino-10-methylfolic acid", "4-amino-10-methylfolic acid", "4-amino-10-methylpteroyl-L-glutamic acid", "4-amino-10-methylpteroyl-L-glutamic acid", "4-amino-4-deoxy-10-methylpteroyl-L-glutamic acid", "4-amino-4-deoxy-10-methylpteroyl-L-glutamic acid", "N-[4-((2, 4-diaminopteridin-6-yl)methylamino)benzoyl]-L-(-)-glutamic", acid, "N-[4-((2, 4-diaminopteridin-6-yl)methylamino)benzoyl]-L-(-)-glutamic", acid, Amethopterin, Amethopterine, Antifolan, CL-14377, "EMT 25299", Emtezate, HDMTX, Ledertrexate, Metatrexan, Methopterin, Methotrexatum, MTX, NCIC04671, NSC-740, R9985, WR-19039, "amethopterin 51865793", "antineoplastic/ cytotoxic/ immunosuppressi"

Section 2 - HAZARDS IDENTIFICATION

EMERGENCY OVERVIEW
RISK
May impair fertility. May cause harm to the unborn child. Toxic by inhalation, in contact with skin and if swallowed. Irritating to eyes, respiratory system and skin.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED
- Toxic effects may result from the accidental ingestion of the material; animal experiments indicate that ingestion of less than 40 gram may be fatal or may produce serious damage to the health of the individual.
- Early side-effects of methotrexate therapy include blood changes (leucopenia, thrombocytopenia), ulceration of the mouth, gastrointestinal effects (diarrhoea). Haemorrhagic enteritis and perforation of the intestine may occur. Bone marrow depression may occur abruptly. Headaches, drowsiness, blurred vision and convulsions are signs of methotrexate toxicity. Liver toxicity may result from acute liver atrophy or cirrhosis. Fatalities have occurred following use.
- In rodents signs of acute toxicity included decreased activity, rapid and laboured breathing, bloody nasal discharge, exophthalmus (abnormal protrusion of the eyeball), diarrhoea, rough fur, piloerection, urinary staining and ataxia. In dogs, acute toxicity was characterised by decreased body weight, stomatitis, emesis, diarrhoea, anorexia, depression, leucopenia and thrombocytopenia.
- The killing action of antineoplastic drugs used for cancer chemotherapy is not selective for cancerous cells alone but affect all dividing cells. Acute side effects include loss of appetite, nausea and vomiting, allergic reaction (skin rash, itch, redness, low blood pressure, unwellness and anaphylactic shock) and local irritation. Gout and renal failure can occur.
- At sufficiently high doses the material may be nephrotoxic (i.e. poisonous to the kidney).
- At sufficiently high doses the material may be hepatotoxic (i.e. poisonous to the liver).

EYE
- Evidence exists, or practical experience predicts, that the material may cause eye irritation in a substantial number of individuals. Prolonged eye contact may cause inflammation characterized by a temporary redness of the conjunctiva (similar to windburn).
- Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

SKIN
- Skin contact with the material may produce toxic effects; systemic effects may result following absorption.
- This material can cause inflammation of the skin on contact in some persons.
- The material may accentuate any pre-existing dermatitis condition.
- Open cuts, abraded or irritated skin should not be exposed to this material.
- Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

INHALED
- Inhalation of dusts, generated by the material, during the course of normal handling, may produce toxic effects.
- The material can cause respiratory irritation in some persons. The body's response to such irritation can cause further lung damage.
- Inhalation of methotrexate may cause gastrointestinal disturbances (nausea and vomiting, loss of appetite, diarrhoea), congestion of the lungs, and cough. Bone marrow suppression (decrease in the ability of the bone marrow to form mature blood cells) and liver damage may be seen.
- Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.

CHRONIC HEALTH EFFECTS
- Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems.
- Based on experiments and other information, there is ample evidence to presume that exposure to this material can cause genetic defects that can be inherited.
- Ample evidence exists from experimentation that reduced human fertility is directly caused by exposure to the material.
- Ample evidence exists, from results in experimentation, that developmental disorders are directly caused by human exposure to the material.
- There has been some concern that this material can cause cancer or mutations but there is not enough data to make an assessment.
- Anti-cancer drugs used for chemotherapy can depress the bone marrow with reduction in the number of white blood cells and platelets and bleeding. Susceptibility to infections and bleeding is increased, which can be life-threatening. Digestive system effects may include inflammation of the mouth cavity, mouth ulcers, esophagus inflammation, abdominal pain and bleeds, diarrhea, bowel ulcers and perforation. Reversible hair loss can result and wound healing may be delayed. Long-term effects on the gonads may cause periods to stop and inhibit sperm production. Most anti-cancer drugs can potentially cause mutations and birth defects, and coupled with the effects of the suppression of the immune system, may also cause cancer.
- Exposure to small quantities may induce hypersensitivity reactions characterized by acute bronchospasm, hives (urticaria), deep dermal wheals (angioneurotic edema), running nose (rhinitis) and blurred vision. Anaphylactic shock and skin rash (non-thrombocytopenic purpura) may occur. An individual may be predisposed to such anti-body mediated reaction if other chemical agents have caused prior sensitization (cross-sensitivity).
- CAUTION: May produce immunosuppression in individuals occupationally exposed to the material.
- Exposure to immunosuppressives may aggravate infectious diseases.
- Chronic exposure to therapeutic doses of compounds which produce immunosuppression has been associated with development of lymphomas (occasionally malignant) and mammary tumours. These may be secondary effects induced by activation of endogenous retroviruses.
- Patients on immunosuppressive medications have a 10- to 100-fold increased risk of cancer compared to the general population. Furthermore, people who currently have or have already been treated for cancer have a higher rate of tumor progression and recurrence than patients with an intact immune system.
- Patients receiving immunosuppressive regimens involving combinations of drugs, as part of an immunosuppressive regimen are at increased risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent.
- Increased incidences of neoplasms, in mice and humans, have been reported after long-term immunosuppression by azathioprine and cyclosporin. Cyclosporin has been classified as a human carcinogen, by IARC, based on development of lymphomas after repeated and prolonged exposures to therapeutic doses.

Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS
SWALLOWED

- Give a slurry of activated charcoal in water to drink. NEVER GIVE AN UNCONSCIOUS PATIENT WATER TO DRINK.
- At least 3 tablespoons in a glass of water should be given.
- Although induction of vomiting may be recommended (IN CONSCIOUS PERSONS ONLY), such a first aid measure is dissuaded because of the risk of aspiration of stomach contents. (i) It is better to take the patient to a doctor who can decide on the necessity and method of emptying the stomach. (ii) Special circumstances may however exist; these include non-availability of charcoal and the ready availability of the doctor.

NOTE: If vomiting is induced, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. NOTE: Wear protective gloves when inducing vomiting.

- REFER FOR MEDICAL ATTENTION WITHOUT DELAY.
- In the meanwhile, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition.
- If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the MSDS should be provided. Further action will be the responsibility of the medical specialist.
- If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the MSDS.

EYE

- If this product comes in contact with the eyes:
  - Immediately hold eyelids apart and flush the eye continuously with running water.
  - Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.
  - Continue flushing until advised to stop by the Poisons Information Center or a doctor, or for at least 15 minutes.
  - Transport to hospital or doctor without delay.

SKIN

- If skin or hair contact occurs:
  - Quickly but gently, wipe material off skin with a dry, clean cloth.
  - Immediately remove all contaminated clothing, including footwear.
  - Wash skin and hair with running water. Continue flushing with water until advised to stop by the Poisons Information Center.
  - Transport to hospital, or doctor.

INHALED

- If fumes or combustion products are inhaled remove from contaminated area.
- Lay patient down. Keep warm and rested.
- Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures.
- Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary.
- Transport to hospital, or doctor without delay.

NOTES TO PHYSICIAN

- Treat symptomatically.

For employees potentially exposed to antineoplastic and/or cytotoxic agents on a regular basis, a preplacement physical examination and history (noting risk factors) is recommended. Periodic follow-up examinations should also be undertaken and should be overseen by a physician familiar with the toxic effects of the substance and full details of the nature of work undertaken by the employee. Following administration of antineoplastics, control of nausea and vomiting may be attempted by giving phenothiazines such as perphenazine, prochlorperazine, promethazine or thiethylperazine before antineoplastic agents are administered. In bone-marrow depression, transfusion of blood or platelets reduces the risk of life-threatening hemorrhage. Granulocyte transfusions and injection of antibiotics may be necessary to combat infection in the neutropenic patient. Hyperuricemia is avoided by the addition of allopurinol to treatment schedules and measures such as alkalization of the urine and hydration may be adopted. MARTINDALE: The Extra Pharmacopoeia, 28th Edition.

Folinic acid neutralises the immediate toxic effects of methotrexate on bone marrow. Methotrexate is rapidly absorbed from the gastrointestinal tract and is distributed in the extracellular spaces and penetrates cell membranes. Small amounts diffuse in the cerebrospinal fluid. About 50% is bound to plasma protein and biphasic and triphasic blood clearance has been reported. The majority of the dose appears in the urine, unchanged within 24 hours. Bound methotrexate may be retained in the body for months.
Section 5 - FIRE FIGHTING MEASURES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vapour Pressure (mmHG)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available.</td>
</tr>
<tr>
<td>Specific Gravity (water=1)</td>
<td>Not available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available</td>
</tr>
</tbody>
</table>

EXTINGUISHING MEDIA
- Foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.
- Water spray or fog - Large fires only.

FIRE FIGHTING
- Alert Emergency Responders and tell them location and nature of hazard.
- Wear full body protective clothing with breathing apparatus.
- Prevent, by any means available, spillage from entering drains or water course.
- Use fire fighting procedures suitable for surrounding area.
- DO NOT approach containers suspected to be hot.
- Cool fire exposed containers with water spray from a protected location.
- If safe to do so, remove containers from path of fire.
- Equipment should be thoroughly decontaminated after use.

GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS
- Combustible solid which burns but propagates flame with difficulty.
- Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust may burn rapidly and fiercely if ignited.
- Dry dust can be charged electrostatically by turbulence, pneumatic transport, pouring, in exhaust ducts and during transport.
- Build-up of electrostatic charge may be prevented by bonding and grounding.
- Powder handling equipment such as dust collectors, dryers and mills may require additional protection measures such as explosion venting.

Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), nitrogen oxides (NOx), other pyrolysis products typical of burning organic material.
- May emit poisonous fumes.

FIRE INCOMPATIBILITY
- Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids, chlorine bleaches, pool chlorine etc. as ignition may result.

PERSONAL PROTECTION
- Glasses: Safety Glasses.
- Gloves: NEOPRENE
- Respirator: Particulate

Section 6 - ACCIDENTAL RELEASE MEASURES

MINOR SPILLS
- It is recommended that areas handling final finished product have cytotoxic spill kits available.
- Spill kits should include:
  - impermeable body covering,
  - shoe covers,
  - latex and utility latex gloves,
  - goggles,
  - approved HEPA respirator,
  - disposable dust pan and scoop,
  - absorbent towels,
  - spill control pillows,
  - disposable sponges,
  - sharps container,
  - disposable garbage bag and
  - hazardous waste label.

To avoid accidental exposure due to waste handling of cytotoxics:
- Place waste residue in a segregated sealed plastic container.
- Used syringes, needles and sharps should not be crushed, clipped, recapped, but placed directly into an approved sharps container.
- Dispose of any cleanup materials and waste residue according to all applicable laws and regulations e.g. secure chemical landfill disposal.
- Clean up waste regularly and abnormal spills immediately.
- Avoid breathing dust and contact with skin and eyes.
- Wear protective clothing, gloves, safety glasses and dust respirator.
- Use dry clean up procedures and avoid generating dust.
• Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
• Dampen with water to prevent dusting before sweeping.
• Place in suitable containers for disposal.

All personnel likely to be involved in an antineoplastic (cytotoxic) spill must receive practical training in:
• the correct procedures for handling cytotoxic drugs or waste in order to prevent and minimize the risk of spills
• the location of the skill kit in the area
• the arrangements for medical treatment of any affected personnel
• the procedure for containment of the spill, and decontamination of personnel and the environment, including the different procedures for major and minor spills
• the procedure for waste disposal according to the nature and extent of the spill

MAJOR SPILLS

• Clear area of personnel and move upward.
• Alert Emergency Responders and tell them location and nature of hazard.
• Wear full body protective clothing with breathing apparatus.
• Prevent, by any means available, spillage from entering drains or water course.
• Stop leak if safe to do so.
• Contain spill with sand, earth or vermiculite.
• Collect recoverable product into labeled containers for recycling.
• Neutralize/decontaminate residue.
• Collect solid residues and seal in labeled drums for disposal.
• Wash area and prevent runoff into drains.
• After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using.
• If contamination of drains or waterways occurs, advise emergency services.

PROTECTIVE ACTIONS FOR SPILL

From IERG (Canada/Australia)

<table>
<thead>
<tr>
<th>Isolation Distance</th>
<th>25 meters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Downwind Protection Distance</td>
<td>250 meters</td>
</tr>
</tbody>
</table>

FOOTNOTES

1 PROTECTIVE ACTION ZONE is defined as the area in which people are at risk of harmful exposure. This zone assumes that random changes in wind direction confines the vapour plume to an area within 30 degrees on either side of the predominant wind direction, resulting in a crosswind protective action distance equal to the downwind protective action distance.
2 PROTECTIVE ACTIONS should be initiated to the extent possible, beginning with those closest to the spill and working away from the site in the downwind direction. Within the protective action zone a level of vapour concentration may exist resulting in nearly all unprotected persons becoming incapacitated and unable to take protective action and/or incurring serious or irreversible health effects.
3 INITIAL ISOLATION ZONE is determined as an area, including upwind of the incident, within which a high probability of localised wind reversal may expose nearly all persons without appropriate protection to life-threatening concentrations of the material.
4 SMALL SPILLS involve a leaking package of 200 litres (55 US gallons) or less, such as a drum (jerrican or box with inner containers). Larger packages leaking less than 200 litres and compressed gas leaking from a small cylinder are also considered "small spills". LARGE SPILLS involve many small leaking packages or a leaking package of greater than 200 litres, such as a cargo tank, portable tank or a "one-tonne" compressed gas cylinder.
5 Guide 151 is taken from the US DOT emergency response guidebook.
6 IERG information is derived from CANUTEC - Transport Canada.

ACUTE EXPOSURE GUIDELINE LEVELS (AEGL) (in ppm)

AEGL 1: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic nonsensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure.
AEGL 2: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects or an impaired ability to escape.
AEGL 3: The airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening health effects or death.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING

• The National Institute of Health (USA) recommends that the preparation of injectable antineoplastic drugs should be performed in a Class II laminar flow biological safety cabinet and that personnel preparing drugs of this class should wear appropriate personal protective gear. Emphasise controls on containment.
• Avoid all personal contact, including inhalation.
Wear protective clothing when risk of exposure occurs.
Use in a well-ventilated area.
Prevent concentration in hollows and sumps.
DO NOT enter confined spaces until atmosphere has been checked.
DO NOT allow material to contact humans, exposed food or food utensils.
Avoid contact with incompatible materials.
When handling, DO NOT eat, drink or smoke.
Keep containers securely sealed when not in use.
Avoid physical damage to containers.
Always wash hands with soap and water after handling.
Work clothes should be laundered separately.
Launder contaminated clothing before re-use.
Use good occupational work practice.
Observe manufacturer's storing and handling recommendations.
Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.

Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.

- Do NOT cut, drill, grind or weld such containers.
- In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

**RECOMMENDED STORAGE METHODS**
- Glass container.
- Lined metal can, Lined metal pail/drum
- Plastic pail
- Polyliner drum
- Packing as recommended by manufacturer.
- Check all containers are clearly labeled and free from leaks.

For low viscosity materials:
- Drums and jerricans must be of the non-removable head type.
- Where a can is to be used as an inner package, the can must have a screwed enclosure.

For materials with a viscosity of at least 2680 cSt. (23 deg. C) and solids (between 15 C deg. and 40 deg C.):
- Removable head packaging;
- Cans with friction closures and
- low pressure tubes and cartridges may be used.
- Where combination packages are used, and the inner packages are of glass, there must be sufficient inert cushioning material in contact with inner and outer packages *.
- In addition, where inner packagings are glass and contain liquids of packing group I and II there must be sufficient inert absorbent to absorb any spillage *.
- * unless the outer packaging is a close fitting molded plastic box and the substances are not incompatible with the plastic.

**STORAGE REQUIREMENTS**
- Antineoplastics (cytotoxics):
  - should be clearly identifiable to all personnel involved in their handling
  - should be stored in impervious break-resistant containers
  - should be stored in separate, clearly marked storage areas to minimize the risk of breakage, and to limit contamination in the event of leakage.

Spill kits should be available in storage areas.
- Store in original containers.
- Keep containers securely sealed.
- Store in a cool, dry, well-ventilated area.
- Store away from incompatible materials and foodstuff containers.
- Protect containers against physical damage and check regularly for leaks.
- Observe manufacturer’s storing and handling recommendations.

**SAFE STORAGE WITH OTHER CLASSIFIED CHEMICALS**

![X X + X X +]

X: Must not be stored together
O: May be stored together with specific preventions
+: May be stored together

**Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION**

**EXPOSURE CONTROLS**
The following materials had no OELs on our records

**MATERIAL DATA**

**METHOTREXATE:**
- It is the goal of the ACGIH (and other Agencies) to recommend TLVs (or their equivalent) for all substances for which there is evidence of health effects at airborne concentrations encountered in the workplace.
At this time no TLV has been established, even though this material may produce adverse health effects (as evidenced in animal experiments or clinical experience). Airborne concentrations must be maintained as low as is practically possible and occupational exposure must be kept to a minimum.

NOTE: The ACGIH occupational exposure standard for Particles Not Otherwise Specified (P.N.O.S) does NOT apply.

Sensory irritants are chemicals that produce temporary and undesirable side-effects on the eyes, nose or throat. Historically occupational exposure standards for these irritants have been based on observation of workers’ responses to various airborne concentrations. Present day expectations require that nearly every individual should be protected against even minor sensory irritation and exposure standards are established using uncertainty factors or safety factors of 5 to 10 or more. On occasion animal no-observable-effect-levels (NOEL) are used to determine these limits where human results are unavailable. An additional approach, typically used by the TLV committee (USA) in determining respiratory standards for this group of chemicals, has been to assign ceiling values (TLV C) to rapidly acting irritants and to assign short-term exposure limits (TLV STELs) when the weight of evidence from irritation, bioaccumulation and other endpoints combine to warrant such a limit. In contrast the MAK Commission (Germany) uses a five-category system based on intensive odour, local irritation, and elimination half-life. However this system is being replaced to be consistent with the European Union (EU) Scientific Committee for Occupational Exposure Limits (SCOEL); this is more closely allied to that of the USA. OSHA (USA) concluded that exposure to sensory irritants can:

- cause inflammation
- cause increased susceptibility to other irritants and infectious agents
- lead to permanent injury or dysfunction
- permit greater absorption of hazardous substances and
- acclimate the worker to the irritant warning properties of these substances thus increasing the risk of overexposure.

**CEL TWA: 0.001 mg/m3.**

**PERSONAL PROTECTION**

Consult your EHS staff for recommendations

**EYE**

- Chemical protective goggles with full seal
- Shielded mask (gas-type)
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59]

**HANDS/FEET**

- Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:
  - frequency and duration of contact,
  - chemical resistance of glove material,
  - glove thickness and
  - dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).

- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
- Contaminated gloves should be replaced.

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

- Rubber gloves (nitrile or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.
- Double gloving should be considered.
- PVC gloves.
- Protective shoe covers.
- Head covering.

**OTHER**

- When handling antineoplastic materials, it is recommended that a disposal work-uniform (such as Tyvek or closed front surgical-type gown with knit cuffs) is worn.
- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities over 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Eye wash unit.
- Ensure there is ready access to an emergency shower.
- For Emergencies: Vinyl suit

- Respirators may be necessary when engineering and administrative controls do not adequately prevent exposures.
- The decision to use respiratory protection should be based on professional judgment that takes into account toxicity information, exposure measurement data, and frequency and likelihood of the worker's exposure - ensure users are not subject to high thermal loads which may result in heat stress or distress due to personal protective equipment (powered, positive flow, full face apparatus may be an option).
- Published occupational exposure limits, where they exist, will assist in determining the adequacy of the selected respiratory protection. These may be government mandated or vendor recommended.
- Certified respirators will be useful for protecting workers from inhalation of particulates when properly selected and fit tested as part of a complete respiratory protection program.
- Use approved positive flow mask if significant quantities of dust becomes airborne.
- Try to avoid creating dust conditions.

**GLOVE SELECTION INDEX**

Glove selection is based on a modified presentation of the: "Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the computer-generated selection: methotrexate

- Protective Material CPI *

**NEOPRENE**

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

**RESPIRATOR**

<table>
<thead>
<tr>
<th>Protection Factor</th>
<th>Half-Face Respirator</th>
<th>Full-Face Respirator</th>
<th>Powered Air Respirator</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 x PEL</td>
<td>P1</td>
<td>-</td>
<td>PAPR-P1</td>
</tr>
<tr>
<td>Air-line*</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>50 x PEL</td>
<td>Air-line**</td>
<td>P2</td>
<td>PAPR-P2</td>
</tr>
<tr>
<td>100 x PEL</td>
<td>-</td>
<td>P3</td>
<td>Air-line*</td>
</tr>
<tr>
<td>100+ x PEL</td>
<td>-</td>
<td>Air-line**</td>
<td>PAPR-P3</td>
</tr>
</tbody>
</table>
| * - Negative pressure demand ** - Continuous flow

Explanation of Respirator Codes:
Class 1 low to medium absorption capacity filters.
Class 2 medium absorption capacity filters.
Class 3 high absorption capacity filters.
PAPR Powered Air Purifying Respirator (positive pressure) cartridge.
Type A for use against certain organic gases and vapors.
Type AX for use against low boiling point organic compounds (less than 65°C).
Type B for use against certain inorganic gases and other acid gases and vapors.
Type C for use against sulfur dioxide and other acid gases and vapors.
Type K for use against ammonia and organic ammonia derivatives
Class P1 intended for use against mechanically generated particulates of sizes most commonly encountered in industry, e.g. asbestos, silica.
Class P2 intended for use against both mechanically and thermally generated particulates, e.g. metal fume.
Class P3 intended for use against all particulates containing highly toxic materials, e.g. beryllium.
The local concentration of material, quantity and conditions of use determine the type of personal protective equipment required.
Use appropriate NIOSH-certified respirator based on informed professional judgement. In conditions where no reasonable estimate of exposure can be made, assume the exposure is in a concentration IDLH and use NIOSH-certified full face pressure demand SCBA with a minimum service life of 30 minutes, or a combination full facepiece pressure demand SAR with auxiliary self-contained air supply. Respirators provided only for escape from IDLH atmospheres shall be NIOSH-certified for escape from the atmosphere in which they will be used.

**ENGINEERING CONTROLS**

- Unless written procedures, specific to the workplace are available, the following is intended as a guide:
  - For Laboratory-scale handling of Substances assessed to be toxic by inhalation. Quantities of up to 25 grams may be handled in Class II biological safety cabinets *. Quantities of 25 grams to 1 kilogram may be handled in Class II biological safety cabinets * or equivalent containment systems Quantities exceeding 1 kg may be handled either using specific containment, a hood or Class II biological safety cabinet*.
  - HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapors.
  - The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated. Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated. When handling: Quantities of up to 25 grams, an approved respirator with HEPA filters or cartridges should be considered. Quantities of 25 grams to 1 kilogram, a half-face negative pressure, full negative pressure, or powered helmet-type air purifying respirator should be considered. Quantities in excess of 1 kilogram, a full face negative pressure, helmet-type air purifying, or supplied air respirator should be considered.

Written procedures, specific to a particular work-place, may replace these recommendations

* For Class II Biological Safety Cabinets, Types B2 or B3 should be considered. Where only Class I, open fronted Cabinets are available, glove panels may be added, Laminar flow cabinets do not provide sufficient protection when handling these materials unless especially designed to do so.

For potent pharmacological agents:

**Powders**
To prevent contamination and overexposure, no open handling of powder should be allowed.  
- Powder handling operations are to be done in a powders weighing hood, a glove box, or other equivalent ventilated containment system.  
- In situations where these ventilated containment hoods have not been installed, a non-ventilated enclosed containment hood should be used.  
- Pending changes resulting from additional air monitoring data, up to 300 mg can be handled outside of an enclosure provided that no grinding, crushing or other dust-generating process occurs.  
- An air-purifying respirator should be worn by all personnel in the immediate area in cases where non-ventilated containment is used, where significant amounts of material (e.g., more than 2 grams) are used, or where the material may become airborne (as through grinding, etc.).  
- Powder should be put into solution or a closed or covered container after handling.  
- If using a ventilated enclosure that has not been validated, wear a half-mask respirator equipped with HEPA cartridges until the enclosure is validated for use.

Solutions Handling:  
- Solutions can be handled outside a containment system or without local exhaust ventilation during procedures with no potential for aerosolisation. If the procedures have a potential for aerosolisation, an air-purifying respirator is to be worn by all personnel in the immediate area.  
- Solutions used for procedures where aerosolisation may occur (e.g., vortexing, pumping) are to be handled within a containment system or with local exhaust ventilation.  
- In situations where this is not feasible (may include animal dosing), an air-purifying respirator is to be worn by all personnel in the immediate area. If using a ventilated enclosure that has not been validated, wear a half-mask respirator equipped with HEPA cartridges until the enclosure is validated for use.  
- Ensure gloves are protective against solvents in use.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL PROPERTIES

Solid.  
Does not mix with water.

<table>
<thead>
<tr>
<th>State</th>
<th>Divided solid</th>
<th>Molecular Weight</th>
<th>454.4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melting Range (°F)</td>
<td>383 (decomp)</td>
<td>Viscosity</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Boiling Range (°F)</td>
<td>Not available</td>
<td>Solubility in water (g/L)</td>
<td>Partly miscible</td>
</tr>
<tr>
<td>Flash Point (°F)</td>
<td>Not available</td>
<td>pH (1% solution)</td>
<td>Not available</td>
</tr>
<tr>
<td>Decomposition Temp (°F)</td>
<td>383</td>
<td>Vapour Pressure (mmHG)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Autoignition Temp (°F)</td>
<td>Not available</td>
<td>Specific Gravity (water=1)</td>
<td>Not available</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available</td>
<td>Relative Vapor Density (air=1)</td>
<td>&gt;1</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available</td>
<td>Evaporation Rate</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

APPEARANCE

Yellow to orange-brown crystalline powder; does not mix well with water. Dissolves in solutions of mineral acids and dilute solutions of alkali hydroxides. The USP permits a mixture of 4-amino-10-methylfollic acid and related substances and specifies not less than 94% C20H22N8O5 calculated on an anhydrous basis.

Section 10 - CHEMICAL STABILITY

CONDITIONS CONTRIBUTING TO INSTABILITY

- Presence of incompatible materials.  
- Product is considered stable.  
- Hazardous polymerization will not occur.

STORAGE INCOMPATIBILITY

- Avoid reaction with oxidizing agents.

For incompatible materials - refer to Section 7 - Handling and Storage.

Section 11 - TOXICOLOGICAL INFORMATION

methotrexate

TOXICITY AND IRRITATION

- unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances.

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TOXICITY</td>
<td>IRRITATION</td>
</tr>
<tr>
<td>Intravenous (Human) TDLo:</td>
<td>100 mg/kg</td>
</tr>
<tr>
<td>Intraperitoneal (Rat) LD50:</td>
<td>6 mg/kg</td>
</tr>
<tr>
<td>Subcutaneous (Rat) LD50:</td>
<td>58 mg/kg</td>
</tr>
<tr>
<td>Intravenous (Rat) LD50:</td>
<td>14 mg/kg</td>
</tr>
<tr>
<td>Intravenous (Rat) TDLo:</td>
<td>30 mg/kg</td>
</tr>
<tr>
<td>Oral (Human) TDLo:</td>
<td>43 mg/kg</td>
</tr>
</tbody>
</table>
Ecotoxicity:

For antineoplastics:

**METHOTREXATE:**

Refer to data for ingredients, which follows:

**Section 12 - ECOLOGICAL INFORMATION**
Section 13 - DISPOSAL CONSIDERATIONS

Disposal Instructions
All waste must be handled in accordance with local, state and federal regulations. Legislation addressing waste disposal requirements may differ by country, state and/or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.
A Hierarchy of Controls seems to be common - the user should investigate:
- Reduction
- Reuse
- Recycling
- Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

\textbf{DO NOT} allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.

\begin{itemize}
  \item Antineoplastic (cytotoxic) wastes must be packed directly, ready for incineration, into color-coded, secure, labelled, leak-proof containers sufficiently robust to withstand handling without breaking, bursting or leaking.
  \item Containers of special design are available for particular needs (such as disposal of sharps) and should be used.
  \item Once filled and closed, such containers must never be re-opened.
  \item Immediate containers must bear a nationally accepted symbol or device depicting cytotoxic substances and be labelled with the words: CYTOTOXIC WASTE - INCINERATE in a style of lettering approved by the national/state authority.
  \item Where policies and procedures permit the merging of cytotoxic wastes with medical waste in an outer container used for medical waste, cytotoxic waste must first be placed in identifiable color-coded/labelled cytotoxic containers prior to merging.
  \item Management procedures must ensure that merged medical and cytotoxic waste is subjected to the incineration requirements appropriate for the total destruction of the cytotoxic waste.
\end{itemize}

\textbf{WASTE STORAGE OF CYTOTOXIC WASTES}

For the storage of cytotoxic waste, segregated or merged with medical waste, provide:
- special storage areas with adequate lighting.
- waste security and restriction of access to authorized persons.
- storage areas designed to facilitate easy routine cleaning and maintenance to hygienic standards, or post-spill decontamination.
- storage of cytotoxic waste in standard, identifying bins or other appropriate containers.

\textbf{COLLECTION OF CYTOTOXIC WASTES}

Procedures for the collection of cytotoxic wastes, which are compatible with existing operational needs, and which protect workers, other people and the environment, must be developed.

\begin{itemize}
  \item Waste must be removed from the site by contractors whose workers have been instructed in the protective methods to be used against the hazards involved, and who comply with the safe work practices established by internal and/or national/state policies. Contractors must instruct, train and direct their personnel in the safe and legal handling of cytotoxic wastes.
  \item Contractor's personnel should observe the operating procedures of the waste-generator.
  \item Transport of cytotoxic wastes, through the community, must comply with the appropriate national/state codes.
\end{itemize}

\textbf{DESTRUCTION OF CYTOTOXIC WASTES}

- Destruction of cytotoxic wastes should be carried out in multi-chambered incinerators, licenced for this purpose, operating at 1100\(^\circ\)C or more, with a residence time of at least 1 second.
- Operators must be trained in handling procedures and hazards involved with handling the waste.
- Waste which arrives at the incinerator inappropriately packaged should NOT be returned to the waste generator. An authorized representative of the waste generator must attend the incinerator site to rectify the situation.

---

Section 14 - TRANSPORTATION INFORMATION

\begin{table}
\begin{tabular}{|l|l|l|}
\hline
\textbf{DOT:} & & \\
\hline
\textbf{Symbols:} & None & Hazard class or Division: 6.1 \\
\hline
\textbf{Identification Numbers:} & UN3249 & PG: III \\
\hline
\textbf{Label Codes:} & 6.1 & Special provisions: T1, TP33 \\
\hline
\textbf{Packaging: Exceptions:} & 153 & Packaging: Non-bulk: 213 \\
\hline
\textbf{Packaging: Exceptions:} & 153 & Quantity limitations: \\
\textbf{Quantity Limitations:} & & Passenger aircraft/rail: 5 kg \\
\textbf{Vessel stowage: Cargo} & & \\
\textbf{aircraft only:} & & Vessel stowage: Location: C \\
\textbf{Vessel stowage: Other:} & 40 & \\
\hline
\end{tabular}
\end{table}

Hazardous materials descriptions and proper shipping names: Medicine, solid, toxic, n.o.s.
Air Transport IATA:

<table>
<thead>
<tr>
<th>ICAO/IATA Class:</th>
<th>6.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICAO/IATA Subrisk:</td>
<td>None</td>
</tr>
<tr>
<td>UN/ID Number:</td>
<td>3249</td>
</tr>
<tr>
<td>Packing Group:</td>
<td>III</td>
</tr>
<tr>
<td>Special provisions:</td>
<td>A3</td>
</tr>
</tbody>
</table>

Shipping Name: MEDICINE, SOLID, TOXIC, N.O.S.(CONTAINS METHOTREXATE)

Maritime Transport IMDG:

<table>
<thead>
<tr>
<th>IMDG Class:</th>
<th>6.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMDG Subrisk:</td>
<td>None</td>
</tr>
<tr>
<td>UN Number:</td>
<td>3249</td>
</tr>
<tr>
<td>Packing Group:</td>
<td>III</td>
</tr>
<tr>
<td>EMS Number:</td>
<td>F-A,S-A</td>
</tr>
<tr>
<td>Special provisions:</td>
<td>221 223 944</td>
</tr>
<tr>
<td>Limited Quantities:</td>
<td>5 kg</td>
</tr>
</tbody>
</table>

Shipping Name: MEDICINE, SOLID, TOXIC, N.O.S.(contains methotrexate)

Section 15 - REGULATORY INFORMATION

methotrexate (CAS: 59-05-2, 60388-53-6, 133073-73-1) is found on the following regulatory lists:
- "Canada Non-Domestic Substances List (NDSL)
- "International Agency for Research on Cancer (IARC) - Agents Reviewed by the IARC Monographs"
- "US - California Air Toxics "Hot Spots" List (Assembly Bill 2588) Substances for which production, use or other presence must be reported"
- "US - California Proposition 65 - Priority List for the Development of MADLs for Chemicals Causing Reproductive Toxicity"
- "US - Connecticut Hazardous Air Pollutants"
- "US - Maine Chemicals of High Concern List"
- "US Toxic Substances Control Act (TSCA) - Inventory"

Section 16 - OTHER INFORMATION

LIMITED EVIDENCE
- Cumulative effects may result following exposure*.
- Limited evidence of a carcinogenic effect*.

* (limited evidence).

Germany Hazard classification and labelling of medicines with antineoplastic effects (ATC Code L01 and L02)

<table>
<thead>
<tr>
<th>INN</th>
<th>CAS</th>
<th>Danger</th>
<th>CMR effects</th>
<th>CMR effects</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cat 1&amp;2</td>
<td>Cat 3</td>
<td></td>
</tr>
<tr>
<td>Methotrexat</td>
<td>59-05-2</td>
<td>T</td>
<td>R 46 R 60 R 61</td>
<td>R 23/24/25 R</td>
<td>36/37/38</td>
</tr>
</tbody>
</table>

Ingredients with multiple CAS Nos

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>CAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>methotrexate</td>
<td>59-05-2, 60388-53-6, 133073-73-1</td>
</tr>
</tbody>
</table>

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.

- Classification of the mixture and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references. A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.
- The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: Mar-31-2009
Print Date: Apr-21-2010